Press Release Archive

11.02.2018

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

10.16.2018

U.S. FDA Approves TALZENNA® (talazoparib)

09.27.2018

U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

09.05.2018

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata

08.27.2018

Pfizer, Inc. Issues A Voluntary Nationwide Recall Of One Lot Of Children’s Advil® Suspension Bubble Gum Flavored 4 FL OZ Bottle

08.21.2018

Important Notice Regarding EpiPen Auto-Injector U.S. supply

08.01.2018

XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis

07.31.2018

Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

07.20.2018

U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)

07.13.2018

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

06.29.2018

Hospira Issues Voluntary Nationwide Recall Of Daptomycin For Injection Lyophilized Powder For Solution, Due to Infusion Reactions

06.28.2018

XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis